再生元制药Regeneron（REGN）2024年企业责任报告「NASDAQ」（英文版）（71页）.pdf

1、RESPONSIBILITY REPORT2024 Introduction32024 Highlights4Letter From Lead Independent Director5Letter From Leadership6Our Business 9Our Approach to Responsibility16Pipeline Innovation16Advancing Our Pipeline18Accelerating Our Genetics Capabilities20Ethical Clinical Trials22Access&Affordability24Patien

2、t AdvocacyImproving Lives27Responsible Business28Corporate Governance28Enterprise Risk Management29Ethics&Compliance31Information Security&Data Privacy32Patient Safety&Product Quality34Responsible Sourcing35Healthy&Engaged Workforce35Human Capital Management41Occupational Health&SafetyIntegrity&Exce

3、llence43Environmental Sustainability45Energy&Emissions47Waste49Water50Nature&Biodiversity51Social Impact56Economic DevelopmentSustainable Communities58About This Report59Data Summary62Goals&Progress63Sustainability Accounting Standards Board(SASB)Standards65Global Reporting Initiative (GRI)Content I

4、ndexAppendixTABLE OF CONTENTS2024 Regeneron Responsibility Report2IntroductionImproving LivesIntegrity&ExcellenceSustainable CommunitiesAppendix1.Regeneron patient assistance programs are limited to patients living in the U.S.states and territories.2.Based on 2024 year-end wholesale acquisition cost

5、.3.The average percentage of employee volunteering is based on CECP Giving in Numbers:2024 Edition.4.Relative to 2016 peak baseline.2024 HIGHLIGHTS40product candidates in clinical development12approvals for new indications or populations for existing products in the U.S.,EU and Japan210patient advoc

6、acy and professional societies engaged across 44 disease areas100keligible1 patients given$3.4B2 worth of medicine at no cost through our products patient assistance programs2.7Mexomes sequenced since RGC was founded in 2013Improving the Lives of People With Serious Diseases32%reduction in total rec